Compare Regeneron Pharmaceuticals Inc (REGN) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Vertiv Holdings Co — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Vertiv Holdings Co trades at $300.5 (market cap $116.96B). The key difference: Vertiv Holdings Co is the larger of the two by market cap, and Regeneron Pharmaceuticals Inc pays the higher dividend (0.56%). Which is the better fit depends on your goals.
| REGN | VRT | |
|---|---|---|
Market Cap | $70.79B | $116.96B |
Sector | Health | Technology |
52-Week High | $812.27 | $376.23 |
52-Week Low | $545.46 | $121.82 |
Enterprise Value | $64.74B | $117.73B |
Dividend Yield | 0.56% | 0.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Vertiv (VRT) trades at $291.67, up 0.73% today, with a bearish technical signal but strong fundamental momentum. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 results expected on July 29, 2026. Revenue and net income are projected to grow in 2026, supported by robust demand for AI data center infrastructure, including recent expansions in cooling solutions manufacturing.
The outlook is positive due to AI-driven growth and a $15 billion order backlog, though high valuation multiples and technical weakness pose risks. Analyst consensus is strongly bullish with a $402.92 price target, but investors should monitor execution on growth targets and competitive pressures in the data center equipment market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
